Scarica l'app Stockscreener
1.56
4.88%
-0.08
Outlook Therapeutics Inc Borsa (OTLK) Ultime notizie
Research Analysts Set Expectations for OTLK Q2 Earnings - MarketBeat
HC Wainwright Has Pessimistic Outlook of OTLK Q2 Earnings - Defense World
Q1 Earnings Estimate for OTLK Issued By HC Wainwright - MarketBeat
What is HC Wainwright’s Estimate for OTLK Q1 Earnings? - Defense World
Outlook Therapeutics® Participates in the Virtual Investor 'Top 5 for '25” On-Demand Conference - The Manila Times
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire
Can This First-Ever Approved Ophthalmic Bevacizumab Transform Eye Treatment in 2025? - StockTitan
Outlook Therapeutics' (OTLK) Neutral Rating Reaffirmed at Chardan Capital - MarketBeat
Outlook Therapeutics (NASDAQ:OTLK) Given New $3.00 Price Target at HC Wainwright - MarketBeat
Outlook Therapeutics (NASDAQ:OTLK) Price Target Cut to $3.00 by Analysts at HC Wainwright - Defense World
Outlook Therapeutics’ (OTLK) Neutral Rating Reaffirmed at Chardan Capital - Armenian Reporter
Outlook Therapeutics (NASDAQ:OTLK) Given “Neutral” Rating at Chardan Capital - Defense World
Outlook Therapeutics (NASDAQ:OTLK) Announces Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
Outlook Therapeutics stock target cut to $3 at H.C. Wainwright By Investing.com - Investing.com Nigeria
Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Outlook Therapeutics stock target cut to $3 at H.C. Wainwright - Investing.com India
Outlook Therapeutics (NASDAQ:OTLK) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat
ONS-5010 shows promise in wet AMD treatment, matching Lucentis - MSN
Outlook Therapeutics Reports Strong Earnings and Strategic Progress - MSN
Analyzing Scilex (NASDAQ:SCLX) and Outlook Therapeutics (NASDAQ:OTLK) - Defense World
Outlook Therapeutics, Inc. SEC 10-Q Report - TradingView
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewswire
Outlook Therapeutics Reports Financial Results For First Quarter Of 2025 -February 14, 2025 at 09:07 am EST - Marketscreener.com
Outlook Therapeutics Secures Funding and Board Restructures - MSN
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2025 - TradingView
Outlook Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2024 - Marketscreener.com
Outlook Therapeutics Advances ONS-5010 / LYTENAVA™ BLA Resubmission and Prepares for European Commercial Launch in 2025 - Nasdaq
Outlook Reports Stunning Earnings Turnaround: From $11.2M Loss to $17.4M Profit as European Launch Approaches - StockTitan
Analysts Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) PT at $27.40 - MarketBeat
Outlook Therapeutics (OTLK) to Release Earnings on Wednesday - MarketBeat
Strategic Move: Biologics Deal-Making Veteran Takes CBO Role at Sonnet BioTherapeutics - StockTitan
Outlook Therapeutics (OTLK) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives $27.40 Consensus Target Price from Analysts - Defense World
Outlook Therapeutics (OTLK) Expected to Announce Earnings on Wednesday - MarketBeat
Outlook Therapeutics Inc (NASDAQ: OTLK) Has Succeeded In Attracting Investors This Year, The Stock Is Down -9.52% Year-To-Date – Marketing Sentinel - Marketing Sentinel
Holdings of Outlook Therapeutics Inc (OTLK) are aligned with the stars - SETE News
Outlook Therapeutics Inc (OTLK) produces promising results - US Post News
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):